300529.SZ
健帆生物
SZSE · Healthcare · C 制造业 · CN
CNY 15.56
−1.27%Year over year
Reported trailing growth
- Revenue
- -18.4%
- EBITDA
- —
- EBIT
- -23.3%
- EPS
- -19.0%
- Free cash flow
- -12.2%
- Operating cash flow
- -12.9%
Forward estimates
Based on analyst estimates
- Revenue
- -76.2%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -6.9%
- EBITDA
- -9.4%
- EBIT
- -12.5%
- Net income
- -15.7%
- EPS
- -14.9%
- Free cash flow
- +10.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026